netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 2: Cardiovascular system - Full Chapter
Chapter Links...
Link   OCCG Guidelines: Direct Oral Anticoagulants (DOACs) for treatment and secondary prevention of DVT and PE in primary care
Link   OCCG Guidelines: Primary care prescriber decision support for Direct Oral Anticoagulants (DOACs) for stroke prevention in atrial fibrillation
Link   OCCG Guidelines: The management of heart failure in primary care
Link   OCCG Guidelines: Lipid modification guidance
 Details...
02.12  Expand sub section  Lipid-regulating drugs
 link Link    NICE CG181: Lipid modification
 link Link    NICE therapeutic topic: Lipid-modifying drugs
 link Link    MHRA: Diabetes risk and statins
 link Link    MHRA: Statin side effects and benefits
 link Link    NICE therapeutic topic: Omega-3 fatty acid supplements
 link Link    NICE: schizophrenia - omega-3 fatty acid medicines
 link Link    OCCG Guidance: Lipid modification Guidance
 link Link    PrescQIPP: Omega 3 fatty acids review
 link Link    UKMI Q&A: Can fish oils protect against photosensitivity disorders?
 link Link    UKMI Q&A: Do statins cause alopecia?
 link Link    UKMI Q&A: Do statins cause amnesia?
 link Link    UKMI Q&A: Erythromycin interaction with statins
 link Link    UKMI Q&A: Evidence for the use of statins in patients with renal impairment
 link Link    UKMI Q&A: Should patients on statins take Coenzyme Q10 to reduce the risk of statin-induced myopathy?
 link Link    UKMI suggested drug monitoring schedule
02.12  Expand sub section  Bile acid sequestrants
02.12  Expand sub section  Ezetimibe
02.12  Expand sub section  Fibrates
02.12  Expand sub section  Statins to top
02.12  Expand sub section  Nicotinic acid group
02.12  Expand sub section  Omega-3 fatty acid compounds
02.12  Expand sub section  PCSK9 inhibitors
02.12  Expand sub section  Other lipid modifying agents
 ....
 Non Formulary Items
Omega-3-Acid Ethyl Esters  (Omacor®)

View adult BNF View SPC online View childrens BNF 		Non Formulary
Black

Recommendation from NHSE as part of Items which should not routinely be prescribed in primary care: Guidance for CCGs.

See Lipid Modification Guidance.

NB. Omacor contains soya oil. If you are allergic to peanut or soya, do not use this medicinal product.

APCO March 2018.
Link  NICE therapeutic topic: Omega-3 fatty acid supplements
Link  NICE: schizophrenia - omega-3 fatty acid medicines
Link  PrescQIPP: Omega 3 fatty acids review
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
 Display tracking information
click to search medicines.org.uk
 Link to adult BNF
click to search medicines.org.uk
 Link to children's BNF
click to search medicines.org.uk
 Link to SPCs
SMC
 Scottish Medicines Consortium
Cytotoxic Drug
 Cytotoxic Drug
CD
 Controlled Drug
High Cost Medicine
 High Cost Medicine
Cancer Drugs Fund
 Cancer Drugs Fund
NHSE
 NHS England
Homecare
 Homecare
CCG
 CCG

Traffic Light Status Information

Status Description

Red

 Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

 Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

 Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

 Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

 not used  

netFormulary